725 related articles for article (PubMed ID: 22941159)
1. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy.
Cardona K; Zhou Q; Gönen M; Shah MA; Strong VE; Brennan MF; Coit DG
Ann Surg Oncol; 2013 Feb; 20(2):548-54. PubMed ID: 22941159
[TBL] [Abstract][Full Text] [Related]
2. Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival?
Badgwell B; Cormier JN; Krishnan S; Yao J; Staerkel GA; Lupo PJ; Pisters PW; Feig B; Mansfield P
Ann Surg Oncol; 2008 Oct; 15(10):2684-91. PubMed ID: 18649106
[TBL] [Abstract][Full Text] [Related]
3. Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.
Cohen DJ; Newman E; Iqbal S; Chang RY; Potmesil M; Ryan T; Donahue B; Chandra A; Liu M; Utate M; Hiotis S; Pachter LH; Hochster H; Muggia F
Ann Surg Oncol; 2012 Feb; 19(2):478-85. PubMed ID: 21769462
[TBL] [Abstract][Full Text] [Related]
4. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
[TBL] [Abstract][Full Text] [Related]
5. Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction.
Barbour AP; Rizk NP; Gerdes H; Bains MS; Rusch VW; Brennan MF; Coit DG
J Am Coll Surg; 2007 Oct; 205(4):593-601. PubMed ID: 17903735
[TBL] [Abstract][Full Text] [Related]
6. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
[TBL] [Abstract][Full Text] [Related]
7. Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome.
Barbour AP; Rizk NP; Gonen M; Tang L; Bains MS; Rusch VW; Coit DG; Brennan MF
Ann Surg Oncol; 2007 Feb; 14(2):306-16. PubMed ID: 17091329
[TBL] [Abstract][Full Text] [Related]
8. A reliable risk score for stage IV esophagogastric cancer.
Blank S; Lordick F; Dobritz M; Grenacher L; Burian M; Langer R; Roth W; Schaible A; Becker K; Bläker H; Sisic L; Stange A; Compani P; Schulze-Bergkamen H; Jäger D; Büchler M; Siewert JR; Ott K
Eur J Surg Oncol; 2013 Aug; 39(8):823-30. PubMed ID: 23375470
[TBL] [Abstract][Full Text] [Related]
9. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer?
Mansour JC; Tang L; Shah M; Bentrem D; Klimstra DS; Gonen M; Kelsen DP; Brennan MF; Coit DG
Ann Surg Oncol; 2007 Dec; 14(12):3412-8. PubMed ID: 17909917
[TBL] [Abstract][Full Text] [Related]
10. Staging laparoscopy in gastroesophageal and gastric adenocarcinoma: first experience from Pakistan.
Bhatti AB; Haider S; Khattak S; Syed AA
Indian J Cancer; 2014; 51(1):15-7. PubMed ID: 24947089
[TBL] [Abstract][Full Text] [Related]
11. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.
Lorenzen S; Blank S; Lordick F; Siewert JR; Ott K
Ann Surg Oncol; 2012 Jul; 19(7):2119-27. PubMed ID: 22395980
[TBL] [Abstract][Full Text] [Related]
12. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
13. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
[TBL] [Abstract][Full Text] [Related]
14. Staging of adenocarcinoma of the gastroesophageal junction.
Parry K; Haverkamp L; Bruijnen RC; Siersema PD; Offerhaus GJ; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2016 Mar; 42(3):400-6. PubMed ID: 26777127
[TBL] [Abstract][Full Text] [Related]
15. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
16. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
[TBL] [Abstract][Full Text] [Related]
18. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome.
Barbour AP; Rizk NP; Gonen M; Tang L; Bains MS; Rusch VW; Coit DG; Brennan MF
Ann Surg; 2007 Jul; 246(1):1-8. PubMed ID: 17592282
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
[TBL] [Abstract][Full Text] [Related]
20. Treatment of clinical T2N0M0 esophageal cancer.
Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
